Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Sirolimus in the Treatment of Kidney Transplant

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: January 24, 2006
Last updated: March 21, 2007
Last verified: March 2007

The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.

Condition Intervention Phase
Kidney Failure
Kidney Diseases
Drug: Sirolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Renal function at 12 months; Comparison between slopes of glomerular filtration rate (GFR) of one year before versus one year after start on sirolimus

Secondary Outcome Measures:
  • Histological parameters at 12 months
  • Cumulative incidence of biopsy-confirmed acute rejection at 12 months
  • Effect at 12 months on proteinuria, blood pressure, hyperlipidemia, and proteinuria

Estimated Enrollment: 100
Study Start Date: August 2006

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Renal transplantation
  • Biopsy-confirmed chronic rejection
  • Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

Exclusion Criteria:

  • Transplant of any organ other than the kidney
  • Current important infection
  • Acute rejection within 12 weeks prior to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00282217

Albacete, Spain, 2006
Barcelona, Spain, 8035
Cadiz, Spain, 11009
Granada, Spain, 18014
L'Hospitalet de Llobregat, Spain, 8701
La Coruna, Spain, 15006
Madrid, Spain, 28035
Madrid, Spain, 28040
Madrid, Spain, 28034
Malaga, Spain, 29010
Oviedo, Spain, 33006
Sevilla, Spain, 41013
Zaragoza, Spain, 50009
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Spain,
  More Information

No publications provided Identifier: NCT00282217     History of Changes
Other Study ID Numbers: 101467
Study First Received: January 24, 2006
Last Updated: March 21, 2007
Health Authority: Spain: Ministry of Health

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Kidney Failure
Kidney Transplant
Graft Rejection
Kidney Transplantation

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014